Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9.7MCash on Hand
13.8mo Cash Runway
Follow ACXP by emailGet an email when ACXP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ACXP, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Leadership A director, Joseph C. Scodari, a board member since 2021, notified the company of his retirement from the Board effective November 13, 2026. The company said the decision was not due to any disagreement. He will continue as a corporate advisor. Form 8-K · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 29, 2026 ·
Shareholder vote Acurx Pharmaceuticals amended its bylaws, lowering the stockholder meeting quorum from a majority of voting shares to one-third (33⅓%) of voting power outstanding and entitled to vote. Form 8-K · SEC filing
Oct 16, 2026 ·
Shareholder vote Shareholders re-elected David P. Luci and Jack H. Dean as Class II directors, with terms running to 2029, and ratified CohnReznick LLP as auditor for fiscal 2026. Quorum was 52.83% of the 5,471,297 shares outstanding. Form 8-K · SEC filing
Sep 17, 2026 ·
Financing Acurx is registering 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a May 8, 2025 purchase agreement. Form 424B3 · SEC filing
Sep 8, 2026 ·
Financing Registers resale of up to 1,500,000 shares by Lincoln Park Capital Fund under a May 8, 2025 purchase agreement. The company receives no proceeds from these resales but may receive up to $2.8 million more from future share sales to Lincoln Park, after $9.2 million already received. Form S-1 · SEC filing
Sep 1, 2026 ·
Shareholder vote Acurx will hold its 2026 annual meeting virtually on October 16, 2026. Stockholders will elect two Class II directors to three-year terms expiring in 2029 and vote to ratify CohnReznick LLP as the independent auditor for fiscal 2026. Form DEF 14A · SEC filing
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2027 · Phase 2 · Recruiting · ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ACXP holds $9.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations,
an estimated runway of 13.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:63 · High
Cash runway 14 months +18
Shelf registration (S-3, Jul 2025) +10
Going-concern doubt in the latest 10-Q +15These matters raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 5,269,921 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ACXP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACXP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.